CD38 and Hepatic fibrosis: Moreover, the reduced eNAD+ levels observed in patients with liver fibrosis or cirrhosis may be linked to impaired NAD+ biosynthesis, increased NAD+ consumption due to chronic inflammation, and enhanced enzymatic degradation by ectoenzymes such as CD38 or CD203a.